Dasatinib is a drug approved for the treatment of leukemia. Studies have shown it can also prevent the growth of non-small cell lung cancer cells with mutations in the DDR2 and BRAF genes. These mutations alter how the DDR2 and BRAF proteins work.
This study is assessing the safety and effectiveness of dasatinib in patients with advanced squamous cell carcinoma of the lung and a DDR2 mutation, and in patients with advanced non-small cell lung cancer with an inactivating BRAF mutation. Dasatinib is taken orally (by mouth).